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We previously described the pattern of sequence variation in gp120 following persistent infection of rhesus
monkeys with the pathogenic simian immunodeficiency virus SIVmac239 molecular clone (D. P. W. Burns and
R. C. Desrosiers, J. Virol. 65:1843, 1991). Sequence changes were confined largely to five variable regions (Vi
to V5), four of which correspond to human immunodeficiency virus type 1 (HIV-1) gpl20 variable regions.
Remarkably, 182 of 186 nucleotide substitutions that were documented in these variable regions resulted in
amino acid changes. This is an extremely nonrandom pattern, which suggests selective pressure driving amino
acid changes in discrete variable domains. In the present study, we investigated whether neutralizing-antibody
responses are one selective force responsible at least in part for the observed pattern of sequence variation.
Variant env sequences called 1-12 and 8-22 obtained 69 and 93 weeks after infection of a rhesus monkey with
cloned SIVmac239 were recombined into the parental SIVmac239 genome, and variant viruses were generated
by transfection of cultured cells with cloned DNA. The 1-12 and 8-22 recombinants differ from the parental
SIVmac239 at 18 amino acid positions in gpl20 and at 5 and 10 amino acid positions, respectively, in gp4l.
Sequential sera from the monkey infected with cloned SIVmac239 from which the 1-12 and 8-22 variants were
isolated showed much higher neutralizing antibody titers to cloned SIVmac239 than to the cloned 1-12 and 8-22
variants. For example, at 55 weeks postinfection the neutralizing antibody titer against SIVmac239 was 640
while those to the variant viruses were 40 and less than 20. Two other rhesus monkeys infected with cloned
SIVmac239 showed a similar pattern. Rhesus monkeys were also experimentally infected with the cloned
variants so that the type-specific nature of the neutralizing antibody responses could be verified. Indeed, each
of these monkeys showed neutralizing-antibody responses of much higher titer to the homologous variant used
for infection. These experiments unambiguously demonstrate that SIV mutants resistant to serum neutralization arise during the course of persistent infection of rhesus monkeys.

Simian immunodeficiency virus (SIV) is a member of the
lentivirus subfamily of retroviruses. This group also includes
human immunodeficiency virus (HIV), equine infectious
anemia virus (EIAV), visna virus, and caprine arthritisencephalitis virus. Members of the lentivirus subfamily establish long-term, persistent infections resulting in chronic,
nononcogenic, debilitating disease.
Antigenic variation during persistent infection has been
documented in at least three lentivirus systems, EIAV (22,
23, 32, 41, 42, 47), visna virus (9, 27, 36-39, 43, 50), and
caprine arthritis-encephalitis virus (10, 40). The strongest
evidence for immune selection lies in the EIAV system, in
which disease is characterized by recurrent clinical episodes
of fever, hemolytic anemia, bone marrow depression, lymphoproliferation, immune-complex glomerulonephritis, and
persistent viremia (32). Plasma recovered from an infected
animal can effectively neutralize virus isolated from earlier
febrile episodes but cannot neutralize virus isolated during
subsequent febrile episodes (23, 32, 47). The animals in these
*

studies thus exhibited delayed neutralizing-antibody responses against variant viruses. By inoculating horses with
variant strains of EIAV, type-specific neutralizing-antibody
responses have been generated against variant viruses (23).
Sequence changes responsible for the resistance of variants
to serum neutralization have not been defined.
The emergence of neutralization resistant HIV-1 variants
in HIV-1 infected chimpanzees (35) and in an HIV-1 infected
human (51) has been reported. Sera for neutralization tests
were derived from the individual in which the variants
emerged. These experiments were performed in one direction only since additional sera from individuals naturally or
experimentally infected with variant virus were not available
for reciprocal testing of neutralizing activity. This is problematic since different virus stocks show considerable variation in the efficiency with which they score in neutralization
tests (25, 28). Such inherent differences in the efficiencies
with which virus stocks score in neutralization tests can be
due to a variety of factors, including differences in infectivity
titers, methods of stock preparation, replication rate, particle/infectivity ratios, gpl20 packing density, gpl20 structure,
gpl2O-gp4l affinity, gpl2O-CD4 affinity, design of the assay,
and other ill-defined parameters. It has been noted previously that some strains of HIV-1 (e.g., RF) appear considerably resistant to neutralization, while others (e.g., SF2) are
considerably more sensitive to neutralization (2, 28, 54).

Corresponding author.

t Present address: Department of Oncology, McArdle Laboratory

for Cancer Research, Medical School, University of Wisconsin,
Madison, WI 53706.
j Present address: Department of Molecular and Cellular Biology,
SmithKline Beecham Biologicals, B-1330 Rixensart, Belgium.

4104

NEUTRALIZATION-RESISTANT SIV MUTANTS

VOL. 67, 1993

Thus, the significance of poor neutralization of variant virus
in these previous experiments with HIV-1 (35, 51) is not
entirely clear, since it was not possible to demonstrate
reciprocal effects with reciprocal sera.
In four other studies on immune selection in humans,
HIV-1 isolates were obtained which could not be neutralized
by the patients' own sera, indicating that neutralizationresistant mutants had emerged in these individuals (1, 13, 31,
53). In two of these studies (1, 53), the neutralization assay
which was used has recently been called into question. The
assay, which was based on the detection of viral p24fag
protein, did not control for anti-gag antibodies which may
have been present in the patients' sera. Such anti-gag
antibodies can interfere with the detection of viral p249ag
protein and can result in unreliable neutralization titers (5).
In the other two studies (13, 31), variant viruses were not
tested against control sera to determine to what extent they
were capable of being neutralized. Also, sera from individuals infected with variant virus were not available for
reciprocal testing. Therefore, it is difficult to conclude from
any of the four studies whether mutants specifically resistant
to neutralization by the patient's sera had actually emerged
in these HIV-1-infected individuals.
Rhesus monkeys infected with molecularly cloned SIV
mac239 provide a useful model system for studying immune
selection. More than 50% of rhesus monkeys infected with
this cloned virus develop strong antibody responses to the
virus and become persistently infected for 1 year or more
prior to the development of AIDS (18). By cloning viral
envelope genes from rhesus monkeys over time and obtaining sequential serum samples from them, we have been able
to study not only the evolution of envelope sequences but
also the emergence of neutralization-resistant variants. We
have also been able to infect naive monkeys with molecularly cloned variant viruses and to verify the selectivity of
the neutralizing-antibody responses. In our previous study
on envelope sequence variation, we found that amino acid
changes in discrete segments of gpl20 result from selective
forces operating in vivo (4). Results from our present study
provide strong evidence that the host neutralizing-antibody
response is one of the selective forces driving sequence
change in the SIV envelope and that at least some envelope
variants are indeed neutralization escape mutants.
MATERIALS AND METHODS
Virus. The SIVmac239 pathogenic molecular clone and its
complete sequence have been described previously (18, 19,
34, 45). Molecular clones of env variants T69BL1-12 (variant
1-12) and T93V8-22 (variant 8-22) have also been described
previously (4). The envelope clone pT69BL1-12 was derived
directly from blood of rhesus monkey Mm243-86 at 69 weeks
after initial infection with SIVmac239. The envelope clone
pT93V8-22 was obtained from cells infected with SIV recovered from the same animal 93 weeks after initial infection.
Both env clones contain sequence changes representative of
the more than 15 env clones sequenced from this animal.

Cells and cell lines. Continuously growing human CD4+
cell lines HuT 78 (11), CEMx174 (14), and MT4 (30) were
grown in RPMI 1640 medium plus 10% inactivated fetal calf
serum, glutamine, penicillin, and streptomycin (complete
RPMI). MRC-5 cells (ATCC CCL171; American Type Culture Collection, Rockville, Md.) were grown in basal medium Eagle (BME) (B2900; Sigma Chemical Co., St. Louis,
Mo.) supplemented with 10% fetal bovine serum (not inac-
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tivated), glutamine, penicillin, and streptomycin (complete
BME).
Experimental infection of rhesus monkeys. Two juvenile
rhesus macaques (Macaca mulatta) previously negative for
SIV antibody were selected from the New England Regional
Primate Research Center colony. Mm206-89 and Mm262-89
were inoculated intramuscularly on 23 January 1991 with
virus derived from transfection of cloned viral DNA into
CEMx174 cells. Each of the two animals was inoculated with
virus containing 7 ng of p27 antigen diluted in 1.0 ml of
complete RPMI; Mm206-89 received env variant 1-12 and
Mm262-89 received env variant 8-22. The variant viruses
used for inoculation had been grown in CEMx174 cells for a
total of 12 days. The amount of p27ag protein was measured
by the Coulter SIV Core Ag Assay (Coulter Corp., Hialeah,
Fla.). Cell-free virus stocks for inoculation were prepared by
centrifugation of infected cell cultures and filtration of viral
supematants through 0.45-pLm-pore-size filters. Heparinized
blood samples were collected from the macaques at intervals
after virus inoculation and were used for virus recovery and
for monitoring antibody response. Infection of Mm243-86,
Mm135-88, and Mm206-86 with SIVmac239 has been described previously (4, 20).
Sera. Sequential blood samples were collected at various
intervals after virus inoculation. The whole blood was separated by centrifugation at 1,500 rpm for 10 min. Serum
samples were heat inactivated at 56°C for 30 min, aliquoted,
and stored frozen at either -20 or -70°C. The samples were
quickly thawed at 37°C, and serial twofold dilutions were
made in complete RPMI prior to neutralization.
Construction of recombinant viruses. The pBS subclones of
SIVmac239 have been described previously (18). Briefly,
SIVmac239 provirus was subcloned into 5' left-half
(p239SpSpS') and 3' right-half (p239SpE3') plasmids through
the use of a unique SphI site located near the center of the
viral genome (Fig. 1). The 5' clone used in the present study
was obtained from the original stock (18). The 3' plasmid
was modified to construct the recombinant viruses. The first
modification consisted of removing two SstI sites located in
the flanking cellular sequences of the 3' plasmid (Fig. 1,
triangle 1). This was achieved by cleaving the 3' plasmid
with AflII and BstXI, which cut uniquely in the flanking
cellular sequences outside the region containing the two SstI
sites. This restriction cleavage deleted 1.9 kb of the 3'flanking cellular sequences. The 5' overhang left byAfllI was
filled in with Klenow, and the 3' overhang left by BstXI was
removed with S1 nuclease. The blunt ends were ligated, and
the ligation mixture was used to transform JM109 competent
bacterial cells. A clone (provided by Hilary G. Morrison,
New England Regional Primate Research Center) was selected on the basis of the absence of the two SstI sites. A
bacterial stock of this clone, called p239SpE3'(ASstI), was
used to prepare plasmid DNA (Qiagen, Inc., Chatsworth,
Calif.). The SphI-EcoRI fragment of p239SpE3'(A&SstI), containing all of the 3' viral sequences, was gel purified for later
use. The second modification of the 3' plasmid consisted of
removing a HindIII site located upstream of the SphI site in
the pBS polylinker region (Fig. 1, triangle 2). A two-step
procedure was used for removing the HindIII site. In the first
step, the pBS(-) vector (Stratagene, La Jolla, Calif.) was
cleaved with HindIlL, filled in with Klenow, ligated, and
transformed into Epicurian coli XL1-Blue competent bacterial cells (Stratagene). A bacterial colony containing a
pBS(-) vector with no HindIII site was selected. The
pBS(AHindIII) vector was cleaved by SphI and EcoRI and
was ligated with the gel-purified SphI-EcoRI fragment of
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FIG. 1. Construction of recombinant viruses. The variant envelope gene is shown at the top as an SstI-SstI fragment. The
numbering system is that of Regier and Desrosiers (45). The 5' and
3' subclones of parental SIVmac239 are shown as circles and have
been described previously (18). The relative locations of important
restriction enzyme sites are indicated. Numbered triangles indicate
modifications of the parental plasmids as described in Materials and
Methods. Fragments resulting from cleavage with the enzyme SphI
are shown. Parental virus sequences are indicated by open boxes,
and variant env sequences are shown as a solid box. The wavy line
represents flanking cellular sequences, and the solid line represents
pBS vector sequences. This figure is drawn approximately to scale.

p239SpE3'(ASstI) (described above). The ligation mixture
used to transform E. coli XL1-Blue competent bacterial cells. A clone, called p239SpE3'(AHindI11ASstI), was
selected. This plasmid served as the parental right-half

was

clone and served as the backbone for construction of all
variant viruses. To obtain the parental backbone, plasmid
p239SpE3'(AHindIIIASstI) was cut with HindIII and SstI.
The 2.4-kb HindIII-SstI parental envelope fragment was
purified away from the 5.2-kb backbone by agarose gel
electrophoresis. Variant envelope fragments were obtained
by cutting the original polymerase chain reaction (PCR)
clones with HindIII and SstI. The 2.4-kb HindIII-SstI variant env fragments were ligated with the 5.2-kb parental
backbone, and the ligation mixture was used to transform E.
coli XL1-Blue competent bacterial cells. The initial clones
were selected on the basis of restriction enzyme analysis.
The final recombinants selected were sequenced in the Vi
and V4 regions of env to confirm each variant sequence.
Transfection. Since the complete viral genome was present
on two plasmids, DNA segments were joined prior to
transfection. A 3-p,g portion of each subclone was cut with
SphI (Fig. 1). The enzyme was heat inactivated at 68°C for 10
min, and the DNA was precipitated with ethanol. The DNA
pellet was resuspended in ligase buffer, and T4 DNA ligase
was added. The ligation reaction was incubated overnight at
15°C. After ligation, the DNA was precipitated with ethanol
and resuspended in 12 pul of Tris-EDTA (TE) buffer. The
DNA was added to 1.4 ml of DME-DEAE-dextran solution
(Dulbecco's modified Eagle [DME] medium containing 125
,ug of DEAE-dextran per ml and 50 mM Tris [pH 7.3]). A
12-,ul solution of TE only (no DNA) was added to 1.4 ml of

DME-DEAE-dextran solution to serve as a negative control.
The DME-DEAE-dextran solution containing either DNA or
TE was used to resuspend 5 x 106 CEMx174 cells which had
been split 24 h prior to use. The cells were incubated with the
DNA solution for 40 min at 37°C. After incubation, cells
were washed once with serum-free DME medium and once
with serum-free RPMI 1640 medium. The cells were resuspended finally in 10 ml of complete RPMI medium. The
cultures were split twice weekly at ratios of 1:2 or 1:3. The
cultures were monitored visually for cytopathic effect and
were tested at various intervals after transfection for the
presence of viral p279ag protein by using the Coulter SIV
Core Ag Assay.
Virus stocks for neutralization. Virus stocks for use in
neutralization were prepared from infected CEMx174 cells
approximately 9 to 13 days postinfection. Before the virus
was harvested, infected cells were pelleted and the supernatant was discarded. Complete RPMI medium was added, and
the infected cells were resuspended at a density of 6.0 x 105
viable cells per ml (half-maximal density for CEMx174). The
virus was harvested 48 h later by clarifying the supernatant
by centrifugation and filtering through 0.45-,um-pore-size
filters. Virus was stored in aliquots of 0.5 to 1.0 ml in a liquid
nitrogen vapor tank at approximately -150°C.
Titration of virus. All virus stocks were titered on cloned
MT4 cells to determine the amount of virus to be used in the
neutralization assay. Titrations were performed in 96-well
plates (Falcon MicroTest III) by using serial fivefold dilutions of virus in replicates of seven. The highest dilution of
virus for which all wells were positive for cell killing was
selected as the amount of virus to be used for neutralization.
The dilutions selected for virus stocks of SIVmac239,
T69BL1-12, and T93V8-22 were 1:100, 1:50, and 1:12.5,
respectively.
Cloning of MT4 cells. MT4 cells were cloned by limiting
dilution in 96-well plates by using a feeder layer of irradiated
MRC-5 cells (ATCC 55-X; American Type Culture Collection). Approximately 104 irradiated MRC-5 cells were added
to each well in 100 pl of complete BME. This feeder layer of
cells was incubated at 37°C in a CO2 incubator. After 24 h,
the medium was changed to complete RPMI (100 ptl). MT4
cells were diluted the next day and added to the feeder layer.
The MT4 cells were counted several times, and the counts
were averaged. Three different dilutions were made to yield
a theoretical distribution of 0.167, 0.5, and 1.5 cells per well
in a volume of 50 pul. Then 50 ,ul of each dilution was added
to each of 48 wells. Since it was not possible to distinguish a
single cell on the feeder layer, wells were screened for
clusters of growing MT4 cells several days after plating.
Every 2 to 5 days, a portion of the medium was changed. A
mixture of fresh medium and filtered-conditioned medium
was added to the plates (one-third conditioned medium from
MT4 cells, one-third conditioned medium from MRC-5 cells,
and one-third fresh RPMI 1640 medium). As the cell numbers increased, cells were transferred to larger tissue culture
vessels and only fresh RPMI 1640 medium was added to the
cultures. When the volumes became large enough and the
passage number was still low, the cells were frozen by
standard methods and stored in a liquid-nitrogen vapor tank
at approximately -150°C.
MTT neutralization assay. Neutralization tests were performed by a serum dilution-constant virus method in 96-well
plates. The assay used was modified from one described
previously (7). Sera were heat inactivated prior to dilution. A
25-p.l portion of the appropriate virus dilution, containing 10
to 20 50% cell killing doses for MT4 cells, was mixed with 25
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,u of each serum dilution for the neutralization step. The
virus-serum mixture was incubated in a CO2 incubator. After
1 h at 370C, 3.0 x 103 cloned MT4 cells (50 ,ul) were added
and the plates were returned to the CO2 incubator. On days
4, 7, and 10, fresh RPMI 1640 medium (50 ,ul) was added to
the plates. On day 14, the cells were assayed for viability by
using a modified M7T [3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide (Sigma Chemical Co.)] assay
(6, 8, 33, 46). MTT is a yellow substrate which is cleaved by
the mitochondria of living cells to yield a purple formazan
product. For the MTT assay, 150 ,ul of culture supernatant
was carefully removed from each well of the neutralization
plate and 30 ,ul of MTT solution (1.67 mg/ml in phosphatebuffered saline) was added to each well. The plates were
returned to the incubator for 4 h, during which time black
MTT formazan crystals formed in the wells containing live
cells. After the 4 h, 100 pul of 0.04 N HCl in isopropanol was
added to each well and vigorously mixed by repeated pipetting with a multichannel pipettor. HCl converted the phenol
red in the medium to a yellow color that did not interfere
with the MTT formazan measurement, whereas the isopropanol dissolved the formazan crystals to give a homogeneous purple color suitable for absorbance measurement.
Within 1 h, the absorbance of the plates was read on a
Dynatech MR5000 dual-wavelength enzyme-linked immunosorbent assay reader, using a test wavelength of 570 nm
and a reference wavelength of 630 nm. The neutralization
titer was determined by taking the reciprocal of the highest
dilution of serum that resulted in at least 60% maximal
viability. The stated serum dilutions are those present in the
initial neutralization step prior to the addition of cells.
Radioimmunoprecipitation. Radioimmunoprecipitation assays were performed as described by Kanki et al. (16).
Briefly, CEMx174 cells infected with cloned viruses were
metabolically labeled with [35S]methionine and [35S]cysteine. Virus was pelleted by high-speed centrifugation of
cell-free supernatant. Virions were lysed with detergent, and
the radiolabeled envelope glycoproteins were precipitated
by using an SIV+ rhesus monkey serum previously bound to
protein A-Sepharose CL-4B (3, 17). The complex was
washed, and the labeled protein was eluted in sample buffer
by boiling at 100°C for 3.5 min. The samples were analyzed
in 7.5% polyacrylamide gels. The gels were fixed, dried, and
exposed to Kodak XAR film.
DNA sequencing. The double-stranded plasmid clones
were sequenced by the primer-directed dideoxy-chain termination method (48) with Sequenase (United States Biochemical Corp., Cleveland, Ohio) and internal oligonucleotide
primers synthesized on a Cyclone DNA Synthesizer (Bio-

search, Inc., Burlington, Mass.) 35S-labeled sequencing reactions were electrophoresed on 6% polyacrylamide gels
with 8 M urea. Sequences were analyzed with IBI-Pustell
DNA analysis software.

Nucleotide sequence accession number. The nucleotide
sequences (data not shown) of the TM coding regions for
variants T69BL1-12 and T93V8-22 have been filed with
GenBank as updates to files under accession numbers
M61078 and M61092, respectively.
RESULTS
Recombinant viruses. Seven late-time-point envelope
clones from Mm243-86 were selected for evaluation on the
basis of unique sequence differences in five variable regions
of gp120 (4). The HindIII-SstI fragments of the original
clones were inserted into the parental backbone sequence as
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described in Materials and Methods. The HindIII-SstI fragment encompasses nearly the entire envelope gene including
both SU and TM. The HindIII enzyme cuts at nucleotide
6822 in SU (at amino acid 73, between Glu and Ser [Fig. 2]).
The HindIII cut is upstream of the Vi region; therefore the
HindIII-SstI variant env fragments contained all five variable
regions of gpl20. The SstI enzyme cuts at nucleotide 9230,
three amino acids upstream of the stop codon of TM (Fig. 2);
this was the original SstI site used for cloning the PCRamplified material from the rhesus monkeys.
All seven recombinant clones were used to transfect
CEMx174 cells, a CD4+ human cell line sensitive to SIVmac
infection. Transfected cultures were monitored visually for
cytopathic effect, and portions of the culture supernatants
were tested for viral p27?a9 protein. Three of the seven
variant viruses (T69BL1-12, T93V8-22, and T93BL3-18)
were found to be replication competent in this cell line.
Relative to the other viruses, variant 3-18 appeared to
replicate less efficiently in CEMx174 cells; the extent of
cytopathic effect and the level of p279ag protein were less in
cultures that received the 3-18 variant. Variants 1-12 and
8-22 were thus chosen for further neutralization studies. All
of the remaining cultures, including cells transfected with TE
buffer, were maintained for a total of 30 days, at which time
they were still negative for p278ag protein. Recombinant
clones which were negative for virus production in this
cell line include T69BL1-21, T69LN2-32, T69V7-16, and
T93BL3-25.
Envelope sequences of molecularly cloned variants. The
envelope genes of variants 1-12 and 8-22 were sequenced
completely, and the deduced amino acid sequences were
compared with those of the parental clone, SIVmac239 (Fig.
2). Within the HindIII-SstI envelope fragment used for
constructing the recombinants, there are 23 amino acid
differences between SIVmac239 and variant 1-12 (18 in
gpl20 and 5 in gp4l). There are 28 amino acid differences
between SIVmac239 and variant 8-22 (18 in gpl20 and 10 in
gp4l). This represents 96.6% amino acid identity in gp120
and 97.2 to 98.6% identity in gp4l for the variants relative to
the parental clone. Variants 1-12 and 8-22 have 17 amino acid
differences from each other in gp120 (96.8% identity) and 7
amino acid differences in gp4l (98.0% identity). The vast
majority of amino acid substitutions and deletions in gp120
are clustered in five variable regions (Fig. 2). In gp4l, amino
acid substitutions cluster around the SF8/SE11 neutralization determinant (21) and between amino acids 792 and 804
of the cytoplasmic domain (Fig. 2).
Infection of rhesus monkeys with variant viruses. Recombinant viruses expressing the 1-12 and 8-22 variant envelope
sequences were each inoculated into a juvenile rhesus monkey (Mm206-89 and Mm262-89, respectively), and both
monkeys became infected. The monkeys were known to be
infected since SIV was repeatedly isolated from their blood
over time and they developed strong stable antibody responses to the virus (data not shown). Serum samples from
these two monkeys were obtained regularly and stored for
later use in neutralization tests. Mm206-89, inoculated with
variant 1-12, was sacrificed when death appeared imminent
after persistent infection with SIV for 1.3 years. Mm262-89,
inoculated with variant 8-22, is currently alive at 1.8 years
postinfection. At this time, CD4+ cells in Mm262-89 represented 29% of peripheral blood mononuclear cells and the
CD4/CD8 ratio was 0.7.
Neutralization assay for cloned SIVmac. There are no
neutralization assays reported in the literature which describe the use of cloned SIV with serum from SIV-infected
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FIG. 2. Deduced amino acid sequences of the envelopes of SIVmac239, variant 1-12, and variant 8-22. Dots represent amino acid identity,
and dashes represent deletions. Variable regions Vl through V5 are boxed (4). Brackets labeled "V3" LOOP and C4 refer to the V3 cysteine
loop, which is variable in HIV-1 (49) and the fourth conserved region of HIV-1 which is important for CD4 binding (24). The region marked
SF8/5E11 is a weak, strain-specific neutralization determinant of SIV (21). The signal peptide (SP) cleavage site (52) and the putative anchor
domain (21) are those of SIV. SU, surface protein (gpl20); TM, transmembrane protein (gp4l) (26). The HindIII and SstI sites used for cloning
the variant envelopes into the parental virus are indicated.
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TABLE 1. Reciprocal neutralization experiments

p.i.a (wk)
239 antisera, Mm243-86
0
13
23
37
55
79
102
123
149
1-12 antisera, Mm206-89
0
18
38
46
55
8-22 antisera, Mm262-89
0
18
38
46
55
a

TABLE 2. Control neutralization experiments

Neutralization titer against:

Serum sample and time
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Neutralization titer against:

Serum sample and time

SIVmac239

T69BL1-12

T93V8-22

<20
<20
<20
80
640
160
80
80
40

<20
<20
<20
<20
40
40
20
80
<20

<20
<20
<20
<20
<20
<20
20
40
<20

<20
<20
20
40
<20

<20
160
160
80
20

<20
<20
20
20
<20

<20
<20
40
20
<20

<20
20
20
20
<20

<20
160
160
160
20

p.i., postinfection.

monkeys. In developing a neutralization assay for cloned
SIV, one is limited not only by lack of appropriate simian
cell lines but also by lack of permissive cell lines in general.
Rhesus monkey peripheral blood lymphocytes support the
growth of cloned SIVmac; however, only limited numbers of
peripheral blood lymphocytes can be obtained from a rhesus
monkey at one time and stable growth in culture occurs for
only a limited time span. Cloned SIVmac does replicate well,
however, in CEMx174 and MT4 cells.
A neutralization assay based on killing of MT4 cells by
uncloned SIVmac251 virus has been described previously
(7). Cloned SIVmac could not be used in this assay because
the cloned virus did not kill enough MT4 cells to score in this
assay. To obtain cells sufficiently sensitive to the killing
effects of cloned virus, the MT4 cell line was cloned as
described in Materials and Methods. One cloned cell line,
called MT4 DB1-1, was used for further studies.
Virus titer determinations were performed with the cloned
MT4 cells. With 300,000 cells/ml as described previously (7),
complete cell killing was not achieved with the cloned MT4
cells. However, unlike the uncloned MT4 cells, cloned MT4
cells were capable of growing when seeded at low cell
densities (as low as 30,000 cells per ml) with no effect on
viability. When virus titer determinations were performed
with cloned MT4 cells at the lower cell density of 30,000 cells
per ml, complete cell killing was achieved for all three cloned
viruses (parental SIVmac239, variant 1-12, and variant 8-22).
Using the appropriate dilutions for each virus, pilot neutralization tests revealed that sera from SIV-infected monkeys
could neutralize cloned SIVmac and protect cloned MT4
cells from cell death. This neutralization assay was therefore
used for further experiments.
Emergence of neutralization-resistant variants. By using
the MTT neutralization assay, neutralization titers were
determined for sequential serum samples from five SIVinfected rhesus monkeys to determine whether neutralization-resistant variants had emerged during the course of

p.i.a (wk)
239 antisera, Mm135-88
12
20
52
111
131
239 antisera, Mm206-86
12
24
53
85
137
a

SIVmac239

T69BL1-12

T93V8-22

<20
80
640
20
80

<20
<20
<20
<20
<20

<20
<20
<20
<20
<20

<20
<20
320
80
20

<20
<20
<20
<20
<20

<20
<20
<20
<20
20

p.i., postinfection.

persistent infection. All of the sera were tested against three
cloned viruses (Tables 1 and 2). The same virus stock of each
virus was used for all neutralization tests.
Sequential sera from Mm243-86, infected with parental
cloned SIVmac239, were found to neutralize SIVmac239
much better than they neutralized variant viruses 1-12 and
8-22 (Table 1). The variant envelopes of 1-12 and 8-22 were
cloned from Mm243-86 at 69 and 93 weeks postinfection,
respectively. Sera taken either around or after the time of
isolation of these variant clones had detectable levels of
neutralizing antibodies against the variants, whereas sera
taken prior to cloning did not yield measurable neutralization
titers. Thus, there appeared to be delayed neutralizingantibody responses against the variants in Mm243-86. The
titers of neutralizing antibodies against variant viruses in the
late-time-point sera from Mm243-86, however, never
reached as high a level as against parental SIVmac239.
Sequential sera from two other animals infected with
parental virus (Mml35-88 and Mm206-86) were also tested
(Table 2). Sera from these two animals also neutralized the
parental virus SIVmac239 much better than they neutralized
the two variant viruses (Table 2).
Neutralization titers of sera from Mm243-86, Mm135-88,
and Mm206-86, all infected with SIVmac239, peaked at
approximately 1 year postinfection and subsequently declined as the animals progressed toward AIDS (Tables 1 and
2). The latest serum sample from Mm243-86 was taken at the
time of death from AIDS (149 weeks). The latest samples
from Mm135-88 and Mm206-86 (131 and 137 weeks, respectively) were taken just before death when the animals were
showing signs of AIDS.
Since neutralization titers against any particular virus are
not absolute measurements in any sense, the data with sera
from Mm243-86, Mm135-88, and Mm206-86 in Tables 1 and
2 cannot by themselves be used to argue for the emergence
of neutralization-resistant variants during persistent infection of Mm243-86. It is possible, for example, that stocks of
the 1-12 and 8-22 variants are less efficient than SIVmac239
at scoring in this neutralization assay.
To rule out this possibility and to control internally for the
results, reciprocal neutralization studies were performed
with sera from animals infected with variant virus. Results
from these cross-neutralization tests revealed that each
variant was indeed neutralized best by sera from monkeys
infected with the homologous virus (Table 1). Sera from
Mm206-89, for example, which was inoculated with the 1-12
virus, neutralized 1-12 much better than they neutralized the
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FIG. 3. Radioimmunoprecipitation. Virus was concentrated by
centrifugation of supernatants from radiolabeled cells infected with
one of three cloned viruses: parental SIVmac239, variant 1-12, and
variant 8-22. Virions were disrupted with detergent and were
immunoprecipitated with the following polyclonal sera: SIV(+)
control sera from an SIV-positive monkey; SIV(-) control sera
from an SIV-negative monkey; SIVmac239 week 37, sera from
animal Mm243-86 infected with cloned SIVmac239; 1-12 week 18,
sera from animal Mm206-89 infected with cloned variant 1-12; and
8-22 week 18, sera from animal Mm262-89 infected with cloned
variant 8-22. Lanes labeled M represent molecular mass markers
expressed in kilodaltons.

other cloned viruses (Table 1). The antisera from Mm2O6-89
neutralized SIVmac239 and 8-22, but neutralization was
delayed and the titers were lower. Similarly, sera from
Mm262-89, which was inoculated with the 8-22 virus, neutralized 8-22 better than they neutralized the other cloned
viruses. The antisera from Mm262-89 also neutralized SIV
mac239 and 1-12, but again neutralization was delayed and
the titers were lower against these viruses. At certain time
points postinfection (week 18, for example), neutralization
titers of the 1-12 and 8-22 sera were as much as eightfold
higher (or more) against homologous virus than against
heterologous virus (Table 1).
Neutralization titers of sera from the two animals that
received variant viruses peaked slightly earlier than those of
sera from the three animals that received parental virus;
neutralization titers reached their highest levels by 18 to 46
weeks postinfection and had declined to lower levels after 1
year postinfection (Table 1). Mm2O6-89 died at 66 weeks
postinfection, whereas Mm262-89 is alive at 92 weeks postinfection.
Radioimmunoprecipitation. Week 37 serum from Mm243-86
and week 18 sera from Mm206-89 and Mm262-89 displayed
dramatic differences in neutralization of the homologous
virus versus the heterologous virus (Table 1). The neutralization titer of week 37 sera against the parental virus was
80, while it was less than 20 against each of the two variant
viruses. Conversely, the neutralization titer of week 18 sera
against each variant virus was 160, while it was <20 against
the parental virus. A radioimmunoprecipitation assay was
performed to determine whether these dramatic differences
in neutralization reflected differences in the ability of these
sera to bind parental versus variant envelope sequences. The
radioimmunoprecipitation assay revealed no significant difference in the ability of each sera to precipitate each of the
three envelope proteins (Fig. 3).
DISCUSSION
Seven recombinant clones

sequences of SIVmac239

expressing variant envelope

were constructed so that immune

selection during persistent infection could be studied. The
seven envelopes, originally isolated from Mm243-86, were
selected on the basis of unique sequence differences in five
variable regions in gpl20 (4). Three of seven recombinants
were replication competent in the CD4+ human cell line
CEMx174. Although there were no obvious defects in the
envelope sequences of the four viruses which did not replicate (such as stop codons or frameshifts), it is possible that
some of the individual amino acid changes resulted in the
inability of virus to replicate. Since the recombinants have
been tested on only one human cell line, it is also possible
that some of the variants are replication competent but
limited in their host cell range.
Because variant 3-18 appeared to replicate less efficiently
than the other viruses, our immune selection studies focused
on variants 1-12 and 8-22. As its full name implies,
T69BL1-12 was cloned from PCR-amplified total-cell DNA
prepared from peripheral blood mononuclear cells isolated at
69 weeks postinfection. Variant T93V8-22 was cloned from
PCR-amplified Hirt supernatant DNA prepared from cells
infected with virus isolated at 93 weeks postinfection. Using
variants 1-12 and 8-22 along with SIVmac239, a neutralization assay was developed for these cloned viruses. The assay
was adapted from a procedure described previously for
uncloned SIVmac251 (7). Modifications of the assay for
cloned SIVmac included the use of cloned MT4 cells and
lower cell densities.
To analyze whether neutralizing-antibody responses are
responsible at least in part for selecting amino acid changes
in variable regions of env, it was necessary to determine
neutralization titers for a variety of virus-serum combinations (Tables 1 and 2). One problem with comparing neutralization titers of a particular serum against three different
viruses is normalization of the amount of virus. For the MTT
neutralization assay, the amount of virus to be used was
determined by finding the titer of the virus and taking the
highest dilution of virus which repeatedly and completely
induced cell killing. Therefore, the absolute amount of virus
in each assay may not be the same. Differences in a variety
of other parameters such as replication rate, spike density,
CD4 affinity, and gpl20-gp41 affinity may also affect the
neutralization process and thus influence the neutralization
titers that can be obtained with different viruses. For these
reasons, one-way neutralization studies, such as those with
the HIV-1 system (1, 13, 31, 51, 53), are not sufficient to
prove that specific neutralization-resistant variants have
emerged in individuals during persistent infection.
For the SIVmac studies described in this report, two-way
"reciprocal" neutralization studies were performed. First,
sera taken at various time points postinfection from three
animals infected with parental SIVmac239 were tested
against the three cloned viruses (Tables 1 and 2). Sera from
all three animals neutralized SIVmac239 better than they
neutralized either of the two variants. Sera taken from
Mm243-86 at time points around or after the time of cloning
of 1-12 and 8-22 neutralized each of the two variants, but the
neutralization titers against the variants were lower than
against the parental virus. For the reciprocal experiment,
sera from animals infected with either 1-12 or 8-22 were used
to show that each variant was neutralized best by its
homologous antisera (Table 1). The resistance of the variants
to neutralization is particularly impressive when one considers that they still share 96.6% amino acid identity in gpl20
and 97.2 to 98.6% amino acid identity in gp4l with the
parental SIVmac239. Radioimmunoprecipitation analysis
(Fig. 3) demonstrated that the dramatic differences in neu-
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tralization of the viruses were not associated with any
difference in the overall anti-gp120 antibody reactivity.
Therefore, if gp120 is indeed the major target of neutralizingantibody responses, neutralizing antibodies probably represent only a small fraction of the total anti-gp120 antibody
population. The SIVmac immune-selection studies presented here offer the most definitive evidence to date that
neutralization-resistant variants emerge in an individual during persistent infection with a primate lentivirus.
Reciprocal neutralization tests were reported in one previous EIAV study. Kono et al. (23) had previously inoculated each of five horses with five different variant viruses;
the variant strains had been isolated over time from one
chronically infected horse. There were delayed neutralizingantibody responses against variant strains of EIAV in the
original animal, and type-specific neutralizing-antibody responses were generated in each of the five horses inoculated
with variant viruses. Although some of the sera displayed a
significant amount of cross-reactivity, each EIAV variant
was neutralized best by its homologous antisera. Results
with molecularly cloned SIVmac are similar to these early
results with uncloned EIAV. The availability of cloned
reagents in the SIV system will now allow us to define
genetic determinants for neutralization escape and to further
evaluate the selective forces operating in vivo during persistent infection. Results from this defined system should allow
a clearer understanding of the role of antigenic variation and
immune selection in viral persistence and the pathogenesis
of AIDS.
Attempts to identify neutralization epitopes in the SIV
system indicate that conformational determinants may be
more important than linear determinants (15). Although the
V3 loop is often referred to as the principal neutralizing
determinant of HIV-1, there is no clear evidence to suggest
that V3 epitopes predominate over conformational epitopes
as targets of neutralizing antibody responses during the
natural course of HIV-1 infection in humans. It is not yet
known to what extent neutralizing antibodies in patient sera
are directed at linear versus conformational epitopes, variable versus conserved, or V3 versus other domains. Haigwood et al. (12) have presented evidence for the role of at
least three HIV-1 gp120 variable regions in recognition by
neutralizing antibodies. The cloned SIV variants and other
reagents described in this report will allow detailed investigation of these issues at least in the SIV system.
The studies with SIVmac presented in this paper indicate
that the humoral branch of the immune system is at least one
of the selective forces operating on an array of variants
present in vivo. Cytotoxic T-lymphocyte and antibodydependent cell-mediated cytotoxicity responses could also
conceivably select for variant viral envelope sequences (29,
44). In addition to immune selection, other selective forces
may operate in vivo. For example, there may be selection for
things such as host, cell, and tissue tropism, replication rate,
syncytium-forming ability, CD4 affinity, gpl20-gp41 affinity,
and cytopathic effect. In light of the complexity of lentiviral
diseases, there may indeed be multiple selective forces
operating simultaneously on any one particular envelope
region, and some of these selective forces may be stronger
than others. The well-defined SIVmac system described in
this report should facilitate precise delineation of which
selective forces are most important for driving change in
each variable region.
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